Lekraza holds a press conference for FDA approval
Announcement of achievements and plans for drug research and development,
Cho Wookje, CEO of Yuhan Pharmaceuticals, is delivering welcoming remarks at a press conference held at Conrad Hotel in Yeouido, Seoul on the 23rd. / Photo=Kim Yoon-hwa, Reporter kyh94@, ‘”I think of this achievement as a milestone and will focus more on drug development for the birth of the second and third Lekraza.”‘,
,
, ‘Yuhan Pharmaceuticals CEO Cho Wookje made this statement at a press conference held at Conrad Hotel in Yeouido, Seoul on the 23rd, announcing the FDA approval of a new lung cancer drug. The event was attended by executives from the R&D department, including President Kim Yeol-hong and Vice President Oh Se-woong, who introduced the company’s future drug development strategies.’,
,
, “Yuhan Pharmaceuticals recently received FDA approval for its lung cancer drug Lekraza, developed in-house in combination with Johnson & Johnson’s targeted therapy ‘Librivant’. This marks the first case of an anticancer drug approved by the FDA in South Korea.”,
,
, ‘Lekraza is the first achievement reaped from Yuhan Pharmaceuticals\’ open innovation activities over the past decade. The company has strategically invested in a total of 35 pharmaceutical companies, with 16 of the 33 substances in its pipeline being externally sourced.’,
,
, ‘Currently, the company is dividing its R&D efforts into three areas: cancer, metabolic diseases, and immune diseases, exploring and developing candidate substances. They plan to invest over 250 billion won, more than 20% of this year\’s revenue, in research and development costs.’,
,
,
/Photo=Kim Yoon-hwa, Reporter kyh94@, “Among the drugs expected to become the second and third Lekraza are the solid tumor drug ‘YH32367,’ the non-alcoholic fatty liver disease (NAFLD) treatment ‘BI3006337,’ and the allergy drug ‘YH35324.’ It is expected that a total of six drugs, including these, will enter the clinical trial stage by next year.”,
,
, ‘R&D Director Lee Jeong-mi stated, “We have been actively integrating innovative ideas from external sources based on our internal capabilities to create new value,” adding, “We focus not only on drugs developed by biotech ventures but also show great interest and support in early-stage technologies.”‘,
,
, ‘Yuhan Pharmaceuticals emphasized the importance of its experience in conducting the entire drug development process for Lekraza’s approval. They also considered it a valuable asset that their subsidiary, Yuhan Chemical, was recognized for its capacity to manufacture active pharmaceutical ingredients (API).’,
,
, ‘R&D Head Kim Yeol-hong expressed confidence in the company\’s ability to develop the second and third Lekraza more easily and efficiently by collaborating with partners across all stages of drug development and receiving recognition for their raw material and finished pharmaceutical production capabilities.’,
,
, ‘CEO Cho stated, “We uphold the belief of the late Dr. Yu Ilhan, who said \’We must strive to create good medicine for the nation and our compatriots,\’ and we are making efforts to create good medicine and a better society,” explaining, “For the past ten years, we have adopted open innovation strategies and have been working with biotech ventures and academia to develop innovative drugs.”‘,
,
, ‘He added, “The approval of Lekraza is an achievement of our efforts over the past decade to develop innovative drugs. In the future, we will collaborate more closely with biotech ventures and academia to contribute to the development of the national bio-industry.”‘,
,
,